A PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

Registry ID

402-C-1603

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

REATA PHARMACEUTICALS INC

Start date

2017-09-15

Last update

2017-05-31

Conditions

• ALPORT SYNDROME

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY WITH AN EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF BAY 3401016 IN PARTICIPANTS AGED 18 TO 45 WITH ALPORT SYNDROME
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF LADEMIRSEN (SAR339375) FOR SUBCUTANEOUS INJECTION ADMINISTERED EVERY WEEK IN PATIENTS WITH ALPORT SYNDROME (HERA)

View on source registry